Anika Therapeutics slumps on FDA Monovisc ruling

BEDFORD — Shares of Anika Therapeutics Inc. skidded lower Wednesday after the company said the Food and Drug Administration upheld its decision against approving the company’s osteoarthritis treatment Monovisc.

The company said it will schedule a meeting with the FDA to determine its next steps.


Monovisc is designed to treat pain in patients suffering from osteoarthritis of the knee. It has been on the market in Europe since 2008 and was approved in Canada in 2009.

Anika Therapeutics stock declined $2.57, or 21.5 percent, to $9.38 in midday trading. The company’s shares have traded between $8.07 and $17.70 over the last year.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of